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Robert P. Nelson, Jr.,1,3 Rafat Abonour,1,3 Angie Secrest,3 Elizabeth Cox,3 Jay Baute,3
Cheryl Sullivan,3 Kathleen Kane,3 Michael J. Robertson,1,3 Sherif S. Farag1,3Clofarabine has significant single-agent activity in patients with indolent and aggressive non-Hodgkin lym-
phoma and synergizes with DNA-damaging drugs. Treatment, however, may be associated with severe
and prolonged myelosuppression. We conducted a phase I trial to determine the maximum tolerated
dose (MTD) of clofarabine in combination with high-dose etoposide and cyclophosphamide followed by
autologous peripheral blood stem cell transplantation in patients with refractory non-Hodgkin lymphoma
(NHL). Patients received clofarabine at 30-70 mg/m2/day on days 26 to 22 in successive cohorts, in com-
bination with etoposide 60 mg/kg (day 28), and cyclophosphamide 100 mg/kg (day 26), followed by
filgrastim-mobilized PBSC on day 0. Sixteen patients of median age 57 (range: 32-67) years with diffuse large
B cell (n5 8), follicular (n5 5), or mantle cell (n5 3) lymphoma that was either primary refractory (n5 2)
or relapsed and refractory (n 5 14) were treated at 5 clofarabine dose levels: 30 (n 5 3), 40 (n 5 3), 50
(n 5 3), 60 (n 5 3), and 70 mg/m2/day (n 5 4) in combination with etoposide and cyclophosphamide.
All patients had grade 4 neutropenia and thrombocytopenia. Grade 3-4 nonhematologic toxicity was evenly
distributed across all 5 dose levels, and included diarrhea (n5 3), mucositis (n5 1), nausea (n5 1), revers-
ible elevation of alanine aminotranferease/aspartate aminotransferase (AST/ALT) (n5 1) or bilirubin (n5 1),
and hemorrhagic cystitis (n 5 1); all resolved by day 130 following transplantation. The MTD was not
reached. No treatment-related deaths occurred. At day 130, 13 patients achieved a complete remission
(CR) or unconfirmed CR (CRU), and 2 patients achieved a partial response, for an overall response rate
of 94%. After a median follow-up of 691 days, the 1-year progression-free survival (PFS) and overall survival
(OS) were 63% (95% confidence interval [CI]: 43%-91%) and 68% (95% CI: 49%-96%), respectively. We
recommend clofarabine 70 mg/m2/day  5 days as a phase II dose in combination with high-dose etoposide
and cyclophosphamide for further testing as a preparative regimen in NHL patients undergoing autologous
PBSC transplantation.
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High-dose chemotherapy and autologous stem cell
transplantation (ASCT) remain the most efficacious
therapy for patients with relapsed non-Hodgkin
lymphoma (NHL), althoughonly patientswith chemo-
sensitive disease appear to benefit themost [1]. Patients
whose disease has never responded to therapy are al-
most never salvaged by ASCT, whereas patients whose
relapsed disease is resistant to conventional-dose
chemotherapy salvage have only a 15% to 20% chance
of long-term disease-free survival (DFS) with987
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failure of ASCT remains relapse, indicating the need
for novel and more effective preparative regimens.
The preparative regimens of high-dose etoposide,
cyclophosphamide, and either carmustine (BCNU),
total-body irradiation (TBI), or busulfan have been
commonly used in patients with relapsed or refractory
lymphoma [3-5]. Etoposide and cyclophosphamide
have documented single-agent activity in resistant
lymphoma [6,7], and been shown to be synergistic in
tumor models [8,9]. The extent of single-agent
activity of high-dose BCNU or busulfan in lymphoma
remains undocumented. Furthermore, high-dose
BCNUhas been associated with interstitial pneumoni-
tis (IP) [10] and busulfan with a significant incidence of
sinusoidal obstruction syndrome (SOS), particularly
when combined with high-dose cyclophosphamide or
TBI [11]. Finally, TBI-based regimens have also
been associated with an increased risk of IP and post-
transplant myelodysplasia in patients undergoing
ASCT for lymphoma [12,13].
Clofarabine (2-chloro-2-fluoro-deoxy-9-D-arabi-
nofuranosyladenine) is a second-generation, purine
nucleoside antimetabolite approved for relapsed or re-
fractory pediatric acute lymphoblastic leukemia. In ad-
dition to its clinical activity in patients with relapsed
and/or refractory acute leukemia [14-16], recent
studies have also shown significant single-agent activity
in mature lymphoid malignancies, including chronic
lymphocytic leukemia (CLL) aswell as indolent and ag-
gressive NHL [17-19]. Although pharmacodynamic
studies have suggested that higher doses of
clofarabine may be more efficacious with dose-
dependent accumulation of the active metabolite
clofarabine triphosphate in CLL cells [17], severe
and prolonged myelosuppression has limited testing
of high doses without stem cell support [18,19].
Furthermore, in vitro synergy between clofarabine
and cyclophosphamide has been demonstrated against
lymphoid cells, whereby clofarabine triphosphate,
which inhibits DNA polymerases and ribonucleotide
reductase, impedes DNA damage induced by
cyclophosphamide and other DNA damaging agents
resulting in enhanced apoptotic cell death [20-22].
Based on its significant antilymphoma activity, po-
tential for dose-response effect, and its synergy with
the DNA damaging agents such as cyclophosphamide
and etoposide, we hypothesized that the combination
of clofarabine, etoposide, and cyclophosphamide may
be an effective, novel preparative regimen for patients
with NHL undergoing ASCT, where the limitation of
prolonged myelosuppression would be overcome with
stem cell support. As an initial step in developing this
regimen, we conducted a phase I clinical trial to deter-
mine the maximum tolerated dose (MTD) of clofara-
bine in combination with high-dose etoposide and
cyclophosphamide followed by autologous peripheralblood stem cell (PBSC) transplantation in patients
with relapsed or refractory NHL.PATIENTS AND METHODS
Patient and Donor Eligibility
Patients were eligible if they had primary refrac-
tory or relapsed and refractory diffuse large B cell
(DLBCL), mediastinal B cell, mantle cell lymphoma
(MCL), or diffuse large cell transformation of an indo-
lent lymphoma, or relapsed or refractory follicular
lymphoma (FL) with high FL International Prognostic
Index (FLIPI) [23]. Refractory disease was defined as
failure to achieve at least a partial response to either
first-line chemotherapy (primary refractory) or the
last chemotherapy regimen if given for relapsed disease
(relapsed and refractory). Patients were also required
to be 18 to 70 years old, have a Karnofsky performance
status of $70%, and have adequate organ function
defined by a left ventricular ejection fraction .45%,
corrected gas transfer (DLCO) .50%, estimated cre-
atinine clearance .60 mL/min/1.73 m2, and serum
bilirubin, aminotranferease (AST), and aspartate
aminotransferase (ALT) levels\2  upper limits of
normal. Patients were excluded if they had a prior
autologous or allogeneic transplant, active central
nervous system lymphoma, uncontrolled infection, or
if they were seropositive for human immunodeficiency
virus (HIV). Patients could receive only filgrastim-
mobilized PBSC. The study was approved by the insti-
tutional review board of Indiana University-Purdue
University Indianapolis. All patients and donors gave
written informed consent. The study was conducted
in accordance with the Declaration of Helsinki.
Study Design and Treatment Plan
All patients received the same doses of etoposide
and cyclophosphamide, whereas the dose of clofara-
bine was escalated in successive cohorts of 3 to 6
patients (see below). Etoposide was administered as
a single dose of 60 mg/kg (actual body weight) intrave-
nously (i.v.) over 4 hours on day 28, and cyclophos-
phamide was administered at 100 mg/kg (lower of
either actual or ideal body weight) i.v. over 1 hour on
day 26. Clofarabine was administered as a daily
1-hour i.v. infusion for 5 days on days 26 to 22,
with the dose escalated in 5 successive cohorts at the
daily dose levels of 30 mg/kg, 40 mg/kg, 50 mg/kg,
60 mg/kg, and 70 mg/kg. Filgrastim-mobilized
PBSC were infused on day 0. Filgrastim (5 mg/kg/
day) was then administered from day 11 until neutro-
phil recovery to at least 5.0  109/L. PBSC were
mobilized using filgrastim (10 mg/kg/day) for 4 days
and continued until collection was complete. Leuka-
pheresis (3-4 blood volumes) was commenced on day
5 and continued daily for a maximum of 4 days until
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(althoughCD341 cell doses\2 106/kg were permis-
sible for transplantation if the target could not be
reached). PBSC were cryopreserved in 10% DMSO
according to institutional standards until infusion.
All patients received prophylactic antibiotics using flu-
conazole, acyclovir, and ciprofloxacin.
A standard 3 1 3 trial design was to be followed.
Three patients were enrolled on the first clofarabine
dose level. If 1 of 3 patients experienced dose-limiting
toxicity (see definition below) at a given dose level, 3
more patients were to be treated at that dose level. If
no dose-limiting toxicity (DLT) was observed in any
of the 3 patients or in 1 of 6 patients, the dose was esca-
lated to the next level. If 2 ormore patients experienced
DLT, the MTD was exceeded, and 3 additional pa-
tients were to be treated at the next lower dose. All
patients assigned to a dose level were followed until
day130 before dose escalation to the next level began.Definitions
Adverse events were graded using National Cancer
Institute’s Common Terminology Criteria for Adverse
Events (NCI CTCAE v3.0). DLT was defined as any
grade 3 or 4 nonhematologic toxicity (except alopecia,
nausea and vomiting, mucositis, fatigue, and correctable
biochemical abnormalities [eg, electrolyte abnormalities;
glucose elevation] as these are reversible and commonly
observed toxicities following high-dose chemotherapy)
that did not resolve to grade 2 or less by day 130 after
transplantation. As profoundmyelosuppression is an ex-
pected uniform outcome of high-dose chemotherapy to
be mitigated by stem cell support, hematologic toxicity
was not considered in the definition of DLT. The
MTDwas defined as the dose level atwhich2outof 6 pa-
tients experienced DLT.
Neutrophil engraftment was defined as the first
day of 3 consecutive days where the absolute neutro-
phil count (ANC) recovered to .0.5  109/L after
conditioning regimen–induced nadir. Platelet en-
graftment was defined as the first day of the of platelet
count .20  109/L without transfusion for 7 consec-
utive days. Primary engraftment failure was defined
as a failure of neutrophil engraftment by day 128.
Disease response was evaluated at 30 and 100 days
after transplantation, and then every 3 months after
transplantation for 2 years, and every 6months for anad-
ditional year, or until disease progression. Responses
were assessed according to 1999 NCI International
Workshop NHL response criteria [24]. Progression-
free survival (PFS) was measured from the date of trans-
plantation to the date of progression of disease, as previ-
ously defined [24], or death from any cause; patients not
known to have any of these events were censored on the
date of last follow-up. Overall survival (OS) was mea-
sured from the date of transplantation to the date deathfrom any cause, censoring for patients alive on the date
of last follow-up.
Pharmacologic Assays and Pharmacokinetic
Analysis
Bloodwas sampled for assay of clofarabine levels on
day 26 before infusion of the first dose for baseline
values, at the end of the initial infusion, and at 2, 3, 4,
5, 6, and 24 hours after the start of the first dose. In ad-
dition, samples were also collected immediately prior
to, at the end of infusion, and at 6 and 24 hours after
subsequent doses on day25 to day22. Blood samples
(5 mL) were collected in green-stopper vacutainer
tubes containing heparin, immediately placed on ice,
plasma separated within 30 minutes by centrifugation
(1000  g for 10 minutes at 4 C), and then the plasma
stored in cryovials at 280 C until assay. For assays,
samples were thawed, and clofarabine was extracted
fromplasma and quantifiedbyHPLC-MS/MS.Plasma
(100 mL)was buffered to pH5 7.4 (with 100mMphos-
phate buffer), internal standard (chloroadenosine) and
ethyl acetate were added, then the sample was mixed
for 20 seconds and then centrifuged at high speed for
3 minutes. The upper organic phase was transferred
to a new tube, evaporated to dryness, and reconstituted
with mobile phase prior to injection into the HPLC-
MS/MS (API 4000, Applied Biosystems, Foster City,
CA). Analytes were separated with a Zorbax Eclipse
C8 5 mm, 4.6 50 mm column (Agilent Technologies,
Placerville, CA) and gradient mobile phase (acetoni-
trile: 5 mM ammonium acetate), and then detected in
the API 4000 using positivemode.TheQ1/Q3 settings
for clofarabine and chloroadenosine were 304/170 and
302/134, respectively. Standard curves were run for
each batch of plasma samples with a lower limit of
quantification of 1 ng/mL.
Concentration-timedatawereanalyzedbyanoncom-
partmental approach using WinNonlin v4.1 (Pharsight,
Mountain View, CA). The following pharmacokinetic
parameters were calculated for clofarabine: maximum
plasma concentration (Cmax), apparent terminal elimina-
tion constant (kel), apparent terminal half-life (t1/2), and
area under the plasma concentration–time curve from
time zero (start of infusion) to the last concentration for
each day of infusion, and the average area under the curve
(AUC) following each dose of clofarabine was also calcu-
lated (AUCav) for eachpatient. In addition, the area under
the plasma concentration curve extrapolated to infinity
(AUC0/N) analyzed fromplasma levels obtained follow-
ing the first clofarabine dose (day26)was also calculated.
The systemic clearance (Cl) was calculated from the dose
and AUC0/N.
Statistical Analysis
The primary objective in this phase I trial was to
determine the MTD of clofarabine when used in
Table 1. Patient Characteristics
N 5 16
Age, median (range) years 57 (32-67)
Gender, male (n) 7
Disease, (n)
Diffuse large B cell lymphoma (DLBCL) 8
Follicular lymphoma (FL) 5
Mantle cell lymphoma (MCL) 3
Disease status, n
Primary refractory 2
First relapsed, refractory 7
Second relapse, refractory 3
Third relapse, refractory 4
Lines of prior treatment, median (range) 3 (2-6)
CD34 count, median (range) 106/kg 1.9 (0.9-3.7)
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phamide for ASCT. Secondary objectives were to
determine the safety and tolerability of this combina-
tion, the response rate, PFS, and OS. Summary
statistics were used to describe baseline patient charac-
teristics, times to engraftment, and response rates. PFS
and OS were estimated using the Kaplan-Meier
method. Safety was monitored by an independent
Data Safety Monitoring Board according to institu-
tional requirements.RESULTS
Patient Characteristics
Sixteen patients were enrolled on study between
September 2007 and September 2009. Patient charac-
teristics are summarized in Table 1. The median age
was 57 (range: 32-67) years. Eight patients had
DLBCL, 5 had FL (4 of whom with histologic grade
3), and 3 had MCL. All patients enrolled had
chemotherapy-refractory disease at time of entry into
the study; 2 had primary refractory disease, 7 were
in refractory first relapse, and 7 in refractory second
or third relapse. Because of the chemotherapy-
refractory nature of their disease, patients were notTable 2. Clinically Significant Toxicity*
Cl
30 mg/m2 (n 5 3) 40 mg/m2 (n 5 3)
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Gr
Mucositis 2 1 2 0
Diarrhea 3 1 3 0
Nausea and vomiting 3 0 3 1
AST/ALTelevation 2 0 3 0
Bilirubin elevation 3 1 3 0
Alkaline phosphatase
elevation
2 0 1 0
Hand-foot syndrome 2 0 0 0
Hemorrhagic cystitis 0 1 0 0
Peripheral neuropathy 1 0 0 0
AST/ALT indicates alanine aminotranferease/aspartate aminotransferase.
*All toxicity resolved to at least grade 1 before day +30 after transplantation.eligible for transplantation on standard protocols. Pa-
tients received a median of 3 (range: 2-6) prior lines of
treatment, including an anthracycline-containing reg-
imen. All patients received PBSC with a median
CD341 cell dose of 1.9 (range: 0.9-3.7)  106/kg.Engraftment
All patients had successful neutrophil and platelet
engraftment. The median time to reaching an ANC
.0.5  109/L was 10 (range: 9-13) days. The median
time to achieving a platelet count .20  109/L was
16 (range: 10-33) days.Toxicity
The distribution of clinically significant grade 1-2
and 3-4 nonhematologic toxicities according to clofara-
bine dose level is shown in Table 2. The most com-
monly observed grade 3-4 toxicities were diarrhea
(n5 3), andnausea andvomiting (n5 2).Grade3-4mu-
cositis, elevation of transaminases, elevation of biliru-
bin, and hemorrhagic cystitis occurred each in 1
patient only. Elevations of AST and ALT were mostly
grade 1 or 2, and all resolved promptly by day 18 in
all patients, with no long-term sequelae. The peak
ALT and AST levels did not correlate with clofarabine
dose levels, as shown in Figure 1 (data for AST not
shown). Overall, grade 3-4 toxicity did not occur more
frequently with dose-escalation of clofarabine. As all
toxicities resolvedbyday130, they did notmeet the cri-
teria for DLT, and the MTD for clofarabine was not
reached. No treatment-related late adverse events
were observed at the time of last follow-up.
Myelosuppression with grade 4 neutropenia and
thrombocytopenia was observed in all patients. Fever
with neutropenia occurred in 9 patients (3 treated in
each of the 30 and 70 mg/m2/day cohorts, and 1 in
each of the 40, 50, and 60 mg/m2/day cohorts), with
bacteremia documented in 4 cases (Staphylococcus epi-
dermidis [n 5 2], Streptococcus mitis [n 5 1], andofarabine Dose Level
50 mg/m2 (n 5 3) 60 mg/m2 (n 5 6) 70 mg/m2 (n 5 4)
ade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
2 0 3 0 4 0
2 0 2 1 3 1
3 0 2 1 2 0
2 0 1 0 2 1
3 0 2 0 0 0
1 0 0 0 0 0
2 0 0 0 1 0
0 0 0 0 0 0
1 0 1 0 0 0
Figure 1. Peak ALT level reached during first 30 days following trans-
plantation by clofarabine dose level. No significant relationship between
peak ALT level reached and clofarabine dose (P 5 .44; ANOVA) was
observed.
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infections included, herpes simplex stomatitis (n 5 2),
Clostridium difficile enterocolitis (n 5 3), and BK virus
hemorrhagic cystitis (n 5 1). Although all patients
received prophylactic antibiotics, the median duration
of antibiotic usage for active treatment of infections
was 10 days (range: 0-24 days). All patients required
transfusions with blood products. The median number
of units of red blood cell concentrate transfused was 4
(range: 2-10), and the number of apheresis units of
platelets transfused was 3 (range: 2-8). The median
duration of hospitalization was 21 (range: 19-30) days.
Treatment Outcome
Of the 16 patients transplanted with active
chemotherapy-refractory lymphoma, 13 patients
achieved a complete response (CR) or complete re-
sponse, unconfirmed (CRU), and 2 patients achievedTable 3. Patient Outcome
Clofarabine (mg/m2) UPN Disease Status Lines of Prior Therapy
30 1 DLBCL Ref Rel 1 3
2 FL (gr 3) Ref Rel 1 4
3 DLBCL Ref Rel 1 2
40 4 FL (gr 3) Ref Rel 1 2
5 FL (gr 3) Ref Rel 3 5
6 MCL Ref Rel 1 3
50 7 DLBCL Ref Rel 2 3
8 FL (gr 2) Ref Rel 2 6
9 DLBCL Ref Rel 3 6
60 10 DLBCL Prim Ref 2
11 DLBCL Ref Rel 1 3
12 MCL Ref Rel 1 4
70 13 DLBCL Prim Ref 3
14 MCL Ref Rel 2 4
15 DLBCL Ref Rel 3 4
16 FL (gr 3) Ref Rel 3 3
DLBCL indicates diffuse large B cell lymphoma; FL, follicular lymphoma; MCL,
CRU, complete remission, unconfirmed; PR, partial response; NR, no respons
*Response evaluation by computed tomography scans of the chest, abdomen,
involved by lymphoma on day +30 after transplantation.a partial response (PR) on day130 evaluation, for a to-
tal response rate of 94% (Table 3). Only 1 patient,
treated at the clofarabine 30 mg/m2/day dose level, re-
mained refractory to treatment. No treatment-related
deaths were observed, with 15 of 16 patients alive at
day1100; 1 patient treated at the 30 mg/m2/day level
whose disease failed to respond died of progressive
lymphoma on day 162. Of the 15 patients who re-
sponded, 6 have had progression of lymphoma at a me-
dian of 128 (range: 91-481) days after transplantation.
After a median follow-up of 691 (range: 313-1029)
days for surviving patients, the 1-year PFS is 63%
(95% confidence interval [CI]: 43%-91%) and the
1-year OS is 68% (95% CI: 49%-96%) (Figure 2).
Plasma Pharmacokinetics Studies and Clinical
Correlations
The clofarabine pharmacokinetic parameters were
analyzed according to a noncompartment model, and
are summarized in Table 4. Although substantial inter-
patient variability was observed, therewas a statistically
significant linear relationship between Cmax (r
2 5 .33;
P 5 .02) and AUC0/N (r
2 5 .67; P 5 .0001), and
the dose of clofarabine administered (Figure 3A and
B). No significant differences in other pharmacoki-
netic parameters were observed between the different
clofarabine dose groups. Significantly, there was no
correlation between Cmax, AUC0/N, or AUCav with
peak ALT or AST levels (data not shown).DISCUSSION
We describe the first study, to our knowledge,
evaluating high-dose clofarabine in combination with
etoposide and cyclophosphamide as a preparative
regimen prior to autologous hematopoietic stem cellResponse* (Day +30) Progression (Day) Alive Cause of Death
NR +30 No NHL
CR — Yes —
CRU — Yes —
CRU — Yes —
CRU — Yes —
CRU — Yes —
CRU — Yes —
CRU — Yes —
PR +118 No NHL
PR +91 No NHL
CRU +188 No NHL
CR — Yes —
CR +137 Yes —
CR — Yes —
CRU +114 No NHL
CRU — Yes —
mantle cell lymphoma; gr 3, histologic grade 3; CR, complete remission;
e; Ref Rel, refractory relapse; Prim Ref, primary refractory.
and pelvis and by bone marrow examination if bone marrow previously
Figure 2. (A) PFS and (B) OS for all patients. The 1-year EFS and OS
estimates are shown on the respective curves.
Figure 3. Clofarabine pharmacokinetics. (A) Correlation of the maxi-
mal concentration of clofarabine (Cmax) after the first dose with clofar-
abine dose; r2 5 .33; P 5 .02. (B) Correlation of the area under the
plasma concentration–time curve (AUC0/N) with clofarabine dose;
r2 5 .67; P 5 .0001.
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safety of the combination with no MTD reached de-
spite clofarabine doses up to 70 mg/m2/day for 5 days.
Recent reports have indicated that clofarabine has
significant single-agent activity in patients with re-
lapsed and/or refractory NHL [18,19]. Although
repeated cycles of low doses of clofarabine (4 mg/m2
for 5 days) have shown activity in NHL [18], pharma-
codynamic studies suggest that dose escalation of clo-
farabine may show optimal antineoplastic activity. For
example, in a phase I study in patients with acute leu-
kemia testing, doses of 15-55 mg/m2/day for 5 days,
pharmacologic studies showed that although there
was modest, if any, increase in accumulation of clofar-Table 4. Clofarabine Pharmacokinetic Parameters
30 mg/m2 (n 5 3) 40 mg/m2 (n 5 3)
AUCav (h*mg/mL) 11.48 ± 1.32 12.08 ± 1.07
AUC0/N (h*mg/mL) 9.59 ± 2.63 9.66 ± 2.21
Cmax (mg/mL) 2.82 ± 1.24 3.43 ± 0.88
Cl (l/h) 5.80 ± 1.04 8.05 ± 2.15
t1/2 (h) 6.50 ± 1.05 5.66 ± 1.34
kel (h
21) 0.13 ± 0.02 0.13 ± 0.03
AUC0/N indicates area under the plasma concentration–time curve from tim
farabine; AUCav, average AUC for the 5 doses of clofarabine given on days26 t
life; kel, elimination constant.
All results expressed as mean 6 standard deviation.abine triphosphate in leukemic blasts with doses be-
yond 30 mg/m2/day, there was a significant dose-
dependent increase in sustained inhibition of replica-
tion of leukemic blasts over 24 hours, with only the
highest dose tested of 55 mg/m2/day leading to com-
plete sustainability of DNA synthesis inhibition
until the next dose [16]. Similarly, in CLL patients,
a dose-dependent accumulation of clofarabine triphos-
phate was observed in peripheral blood leukemicClofarabine Dose Level
50 mg/m2 (n 5 3) 60 mg/m2 (n 5 3) 70 mg/m2 (n 5 4)
14.92 ± 1.41 22.66 ± 13.58 23.38 ± 7.00
14.67 ± 2.09 23.70 ± 8.06 22.98 ± 4.36
3.15 ± 0.74 3.87 ± 2.43 5.51 ± 1.60
6.32 ± 1.07 5.02 ± 1.28 3.79 ± 2.35
4.17 ± 0.38 4.31 ± 0.04 4.04 ± 0.51
0.17 ± 0.02 0.16 ± 0.01 0.17 ± 0.02
e 0 to infinity calculated from levels obtained after the first dose of clo-
o22; Cmax, maximum concentration; Cl, clearance; t1/2, elimination half-
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m2 [17]. Although no study has examined clofarabine
triphosphate accumulation in lymphoma cells relative
to dose, the latter pharmacologic studies do suggest
that dose-escalation of clofarabinemay achieve optimal
antilymphoma activity given that clofarabine triphos-
phate is the active moiety of the drug, inhibiting
DNA synthesis and repair [21], directly promoting ap-
optosis [25], as well as synergizing with DNA-damag-
ing drugs [22]. When clinically tested in higher doses
(40 mg/m2/day for 5 days) in patients with heavily pre-
treated NHL, however, severe and prolonged myelo-
suppression was limiting [19]. These results
suggested that high-dose clofarabine could be better
tolerated in such a population if used with stem cell
support, and in this setting could be tested in combina-
tion with high-dose etoposide and cyclophosphamide,
which cause DNA damage and are also know to be ac-
tive in NHL.
Importantly, we have shown that in combination
with high-dose etoposide and cyclophosphamide,
clofarabine may be safely escalated to doses up to
70 mg/m2/day, which may be expected to provide
more optimal activity than lower doses. A previous
phase I study in adult patients with acute leukemia
has defined the MTD of single-agent clofarabine
(without stem cell support) as 40 mg/m2/day based
on grade 3-4 transaminase elevations, although these
were completely reversible and asymptomatic [16].
In a recent phase I study of clofarabine and high-
dose busulfan for allogeneic stem cell transplantation
in adults with acute leukemia, asymptomatic and
reversible grade 3-4 transaminase elevations were
similarly observed although hepatotoxicity was not
dose dependent in the range of 30-60 mg/m2/day
for 5 days [26]. In the latter study, as transaminase
elevations were completely reversible within 10
days after transplantation, they did not constitute
DLT [26]. Significantly, in the current study, we
did not observe grade 3-4 AST and ALT elevations
despite escalating clofarabine to 70 mg/m2/day. Al-
though the reasons for the absence of significant
transaminase elevation in this study are unclear, it
is possible the type and intensity of prior therapy
may influence the severity of transaminitis. In this re-
spect, in a phase I trial of patients with advanced
solid tumors, who may have been less intensively
pretreated than refractory leukemia patients, no grade
3-4 transaminitis was observed despite clofarabine
doses of up to 129 mg/m2 (given weekly for 3 weeks
of a 4-week cycle) [27]. Similarly, in a phase I/II trial
of clofarabine in combination with etoposide and cy-
clophosphamide (given in significantly lower doses
without stem cell support) in children with relapsed
and refractory acute leukemia, clofarabine doses of
40 mg/m2/day for 5 days resulted in unexpected hepa-
totoxicity in the form of SOS in the phase II portion ofthe study in patients who had undergone prior myelo-
ablative therapy and stem cell transplantation within
the year preceding study entry and in the context of
concurrent severe infection [28]. Other toxicities ob-
served, including mucositis and diarrhea, are similar
to those previously reported for patients receiving clo-
farabine or high-dose etoposide and cyclophospha-
mide. Therefore, although our data supports further
investigation of high-dose clofarabine, as previously
also suggested by other investigators [29], caution
should be exercised in patients who have received prior
intensive chemotherapy, particularly those receiving
myeloablative therapy.
The plasma pharmacokinetic parameters of
clofarabine in the current study are similar to those pre-
viously published [27,30,31]. Despite substantial
interpatient variability in Cmax and AUC0/N at any
given clofarabine dose there was dose-dependent accu-
mulation of the drug in plasma. Furthermore, despite
dose-dependent accumulation of clofarabine, there
wasno apparent associationbetweenplasmapharmaco-
kinetic parameters and toxicity. However, as we did not
measure levels of cyclophosphamide and etoposide, we
cannot exclude the possibility of any pharmacokinetic
interaction between clofarabine and these drugs.
Although not the primary endpoint, the clinical
outcome of patients treated with the combination
of high-dose clofarabine, etoposide, and cyclophospha-
mide was quite encouraging given the chemotherapy-
refractory nature of the patients treated. The regimen
was well tolerated, with no treatment-related deaths.
Importantly, durable remissions of .1 year were ob-
served in 9 patients, including 2with refractoryDLBCL
and 3 with refractoryMCL, with overall very encourag-
ing 1-year PFS and OS of 63% and 68%, respectively,
despite the refractory nature ofNHL in treated patients.
It should be noted that the majority of patients included
in this study would not otherwise be candidates for
ASCT with standard protocols given the advanced and
chemotherapy-refractory nature of their lymphoma.
This compares favorably with results of previous
studies where the reported 1-year survival for similar
patients has generally been 20% or less with more
conventional chemotherapy- or TBI-based regimens
[1,32]. Although the number of patients in the current
study is too small to make definitive conclusions
regarding efficacy, the results strongly suggest that the
high-dose clofarabine, etoposide, and cyclophospha-
mide regimen should be studied further to determine
its relative efficacy, particularly in patients with high-
risk disease where standard preparative regimens are
associated with poor outcomes.
We conclude that high-dose clofarabine, etoposide,
and cyclophosphamide is a novel andwell-tolerated pre-
parative regimen for NHL patients undergoing ASCT,
with significant antilymphoma activity. Further investi-
gation of this regimen is justified to better assess its
994 Biol Blood Marrow Transplant 17:987-994, 2011S. Srivastava et al.efficacy and safety, with a recommended phase II dose of
clofarabine of 70 mg/m2/day for 5 days in combination
with etoposide (60 mg/kg) and cyclophosphamide
(100 mg/kg).
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